Plasmatech Biopharmaceuticals Inc Stock Nasdaq
Stocks
US72754H1095
Pharmaceuticals
|
End-of-day quote
Nasdaq
|
||
| - USD | - |
|
| 08-14 | Oppenheimer Adjusts PT on Abeona Therapeutics to $21 From $22, Maintains Outperform Rating | MT |
| 08-13 | Abeona Therapeutics Shares Fall After Q2 Miss | MT |
| Market Cap | 347M 297M 278M 254M 479M 33.18B 484M 3.29B 1.28B 16.66B 1.3B 1.27B 55.13B | P/E 2026 * |
-6.35x | P/E 2027 * | -32.2x |
|---|---|---|---|---|---|
| Enterprise Value | 347M 297M 278M 254M 479M 33.18B 484M 3.29B 1.28B 16.66B 1.3B 1.27B 55.13B | EV / Sales 2026 * |
6.38x | EV / Sales 2027 * | 2.92x |
| Free-Float |
79.56% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Plasmatech Biopharmaceuticals Inc
| Manager | Title | Age | Since |
|---|---|---|---|
Vishwas Seshadri
CEO | Chief Executive Officer | 50 | 2021-10-14 |
Joseph Vazzano
DFI | Director of Finance/CFO | 42 | 2022-03-13 |
James A. Gow
CTO | Chief Tech/Sci/R&D Officer | - | 2025-10-19 |
| Director | Title | Age | Since |
|---|---|---|---|
Mark Alvino
BRD | Director/Board Member | 58 | 2006-02-28 |
Faith Charles
BRD | Director/Board Member | 64 | 2021-03-24 |
Leila Alland
BRD | Director/Board Member | 63 | 2021-04-18 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.66% | +2.80% | +40.55% | -0.33% | 83.28B | |
| -4.30% | +115.47% | +412.13% | +23.29% | 57.94B | |
| +2.01% | +9.30% | -20.29% | -34.52% | 57.77B | |
| +1.42% | +1.61% | -0.67% | +34.08% | 51.75B | |
| -0.77% | +2.14% | +11.51% | +170.00% | 49.35B | |
| +0.62% | +4.29% | +56.57% | -16.88% | 32.03B | |
| +0.13% | +3.63% | +50.49% | +99.25% | 25.91B | |
| +0.25% | +3.31% | -0.10% | +195.41% | 22.74B | |
| -1.74% | -1.27% | +55.54% | +107.91% | 16.87B | |
| Average | -0.33% | +18.56% | +67.30% | +64.25% | 44.18B | |
| Weighted average by Cap. | -0.38% | +22.64% | +77.14% | +44.70% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 54.34M 46.57M 43.56M 39.83M 75.16M 5.2B 75.96M 515M 200M 2.61B 204M 200M 8.64B | 119M 102M 95.3M 87.12M 164M 11.38B 166M 1.13B 438M 5.72B 446M 437M 18.91B |
| Net income | -54.51M -46.71M -43.7M -39.95M -75.4M -5.22B -76.2M -517M -201M -2.62B -205M -200M -8.67B | -9.22M -7.9M -7.39M -6.76M -12.75M -883M -12.89M -87.46M -34.01M -443M -34.61M -33.86M -1.47B |
| Net Debt | - | - |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Select your edition
All financial news and data tailored to specific country editions
